Skip to main content
Erschienen in: International Urology and Nephrology 5/2017

16.02.2017 | Urology - Original Paper

Comparison of histopathological characteristics of polyacrylate polyalcohol copolymer with dextranomer/hyaluronic acid after injection beneath the bladder mucosa layer: a rabbit model

verfasst von: Abdol-Mohammad Kajbafzadeh, Shabnam Sabetkish, Reza Khorramirouz, Nastaran Sabetkish

Erschienen in: International Urology and Nephrology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To compare short- and long-term local tissue reaction of polyacrylate polyalcohol copolymer (PPC) with dextranomer/hyaluronic acid (DHA) in rabbits.

Methods

Eight healthy New Zealand rabbits were randomly divided into two groups. In group I (control group), DHA was injected just beneath the mucosal layer of the bladder wall, while PPC was injected in group II. Subcutaneous injection of both bulking agents was also performed in nude mice. Histological evaluations with leukocyte common antibody (LCA), CD68, CD31, and CD34 were conducted on biopsies 1 and 6 months postoperatively. Scanning electron microscopy (SEM) and MTT assay were also performed for these two bulking agents.

Results

SEM images revealed larger particle size of PPC. LCA and CD68 staining was significantly higher in group II as compared with group I in both short- and long-term follow-ups. However, in groups I and II, expression of CD31 (101 ± 0.5 vs. 92 ± 0.25, p > 0.05) and CD34 (115 ± 0.75 vs. 103 ± 0.5, p > 0.05) was not significantly different in long-term follow-up. Remarkably, severe fibrosis was observed in group II as compared to mild fibrosis in group I one month after injection. The results of in vivo application of these bulking agents in nude mice were in accordance with the results obtained from rabbit model. MTT assay revealed that cell proliferation was significantly higher in the presence of DHA as compared with PPC.

Conclusion

Severe inflammation and fibrosis in PPC may be due to continued foreign body reaction, presence of alcohol polymers, or larger particle sizes.
Literatur
1.
Zurück zum Zitat Matouschek E (1981) Treatment of vesicorenal reflux by transurethral teflon-injection (author’s transl). Der Urologe Ausg A 20(5):263–264PubMed Matouschek E (1981) Treatment of vesicorenal reflux by transurethral teflon-injection (author’s transl). Der Urologe Ausg A 20(5):263–264PubMed
2.
Zurück zum Zitat O’Donnell B, Puri P (1984) Treatment of vesicoureteric reflux by endoscopic injection of Teflon. J urol 167(4):1808–1809CrossRef O’Donnell B, Puri P (1984) Treatment of vesicoureteric reflux by endoscopic injection of Teflon. J urol 167(4):1808–1809CrossRef
5.
Zurück zum Zitat Chertin B, Puri P (2002) Endoscopic management of vesicoureteral reflux: does it stand the test of time? Eur Urol 42(6):598–606CrossRefPubMed Chertin B, Puri P (2002) Endoscopic management of vesicoureteral reflux: does it stand the test of time? Eur Urol 42(6):598–606CrossRefPubMed
6.
Zurück zum Zitat Malizia AA Jr, Reiman HM, Myers RP, Sande JR, Barham SS, Benson RC Jr, Dewanjee MK, Utz WJ (1984) Migration and granulomatous reaction after periurethral injection of polytef (Teflon). JAMA 251(24):3277–3281CrossRefPubMed Malizia AA Jr, Reiman HM, Myers RP, Sande JR, Barham SS, Benson RC Jr, Dewanjee MK, Utz WJ (1984) Migration and granulomatous reaction after periurethral injection of polytef (Teflon). JAMA 251(24):3277–3281CrossRefPubMed
7.
Zurück zum Zitat Ormaechea M, Ruiz E, Denes E, Gimenez F, Denes FT, Moldes J, Amarante A, Pioner G, Dekermacher S, de Badiola F (2010) New tissue bulking agent (polyacrylate polyalcohol) for treating vesicoureteral reflux: preliminary results in children. J Urol 183(2):714–717. doi:10.1016/j.juro.2009.10.047 CrossRefPubMed Ormaechea M, Ruiz E, Denes E, Gimenez F, Denes FT, Moldes J, Amarante A, Pioner G, Dekermacher S, de Badiola F (2010) New tissue bulking agent (polyacrylate polyalcohol) for treating vesicoureteral reflux: preliminary results in children. J Urol 183(2):714–717. doi:10.​1016/​j.​juro.​2009.​10.​047 CrossRefPubMed
8.
Zurück zum Zitat Stenberg A, Lackgren G (1995) A new bioimplant for the endoscopic treatment of vesicoureteral reflux: experimental and short-term clinical results. J Urol 154(2 Pt 2):800–803PubMed Stenberg A, Lackgren G (1995) A new bioimplant for the endoscopic treatment of vesicoureteral reflux: experimental and short-term clinical results. J Urol 154(2 Pt 2):800–803PubMed
9.
Zurück zum Zitat Lightner D, Rovner E, Corcos J, Payne C, Brubaker L, Drutz H, Steinhoff G, Zuidex Study G (2009) Randomized controlled multisite trial of injected bulking agents for women with intrinsic sphincter deficiency: mid-urethral injection of Zuidex via the Implacer versus proximal urethral injection of Contigen cystoscopically. Urology 74(4):771–775. doi:10.1016/j.urology.2009.05.034 CrossRef Lightner D, Rovner E, Corcos J, Payne C, Brubaker L, Drutz H, Steinhoff G, Zuidex Study G (2009) Randomized controlled multisite trial of injected bulking agents for women with intrinsic sphincter deficiency: mid-urethral injection of Zuidex via the Implacer versus proximal urethral injection of Contigen cystoscopically. Urology 74(4):771–775. doi:10.​1016/​j.​urology.​2009.​05.​034 CrossRef
10.
Zurück zum Zitat Kirsch AJ, Perez-Brayfield M, Smith EA, Scherz HC (2004) The modified sting procedure to correct vesicoureteral reflux: improved results with submucosal implantation within the intramural ureter. J Urol 171(6):2413–2416CrossRefPubMed Kirsch AJ, Perez-Brayfield M, Smith EA, Scherz HC (2004) The modified sting procedure to correct vesicoureteral reflux: improved results with submucosal implantation within the intramural ureter. J Urol 171(6):2413–2416CrossRefPubMed
11.
Zurück zum Zitat Elder JS, Shah MB, Batiste LR, Eaddy M (2007) Part 3: Endoscopic injection versus antibiotic prophylaxis in the reduction of urinary tract infections in patients with vesicoureteral reflux. Curr Med Res Opin 23(Suppl 4 (S4)):S15–S20. doi:10.1185/030079907X226230 CrossRefPubMed Elder JS, Shah MB, Batiste LR, Eaddy M (2007) Part 3: Endoscopic injection versus antibiotic prophylaxis in the reduction of urinary tract infections in patients with vesicoureteral reflux. Curr Med Res Opin 23(Suppl 4 (S4)):S15–S20. doi:10.​1185/​030079907X226230​ CrossRefPubMed
12.
Zurück zum Zitat Caione P, Capozza N (2002) Endoscopic treatment of urinary incontinence in pediatric patients: 2-year experience with dextranomer/hyaluronic acid copolymer. J Urol 168(4 Pt 2):1868–1871CrossRefPubMed Caione P, Capozza N (2002) Endoscopic treatment of urinary incontinence in pediatric patients: 2-year experience with dextranomer/hyaluronic acid copolymer. J Urol 168(4 Pt 2):1868–1871CrossRefPubMed
13.
Zurück zum Zitat Stenberg A, Sundin A, Larsson B, Lackgren G, Stenberg A (1997) Lack of distant migration after injection of A sup 125 iodine labeled dextranomer based implant into the rabbit bladder. J Urol 158(5):1937–1941CrossRefPubMed Stenberg A, Sundin A, Larsson B, Lackgren G, Stenberg A (1997) Lack of distant migration after injection of A sup 125 iodine labeled dextranomer based implant into the rabbit bladder. J Urol 158(5):1937–1941CrossRefPubMed
16.
Zurück zum Zitat Ben-Meir D, Morgenstern S, Sivan B, Efrat R, Livne PM (2012) Histology proved malpositioning of dextranomer/hyaluronic acid in submucosal ureter in patients after failed endoscopic treatment of vesicoureteral reflux. J Urol 188(1):258–261. doi:10.1016/j.juro.2012.03.019 CrossRefPubMed Ben-Meir D, Morgenstern S, Sivan B, Efrat R, Livne PM (2012) Histology proved malpositioning of dextranomer/hyaluronic acid in submucosal ureter in patients after failed endoscopic treatment of vesicoureteral reflux. J Urol 188(1):258–261. doi:10.​1016/​j.​juro.​2012.​03.​019 CrossRefPubMed
17.
Zurück zum Zitat Chertin B, Arafeh WA, Zeldin A, Kocherov S (2011) Preliminary data on endoscopic treatment of vesicoureteric reflux with polyacrylate polyalcohol copolymer (Vantris): surgical outcome following single injection. J Pediatr Urol 7(6):654–657CrossRefPubMed Chertin B, Arafeh WA, Zeldin A, Kocherov S (2011) Preliminary data on endoscopic treatment of vesicoureteric reflux with polyacrylate polyalcohol copolymer (Vantris): surgical outcome following single injection. J Pediatr Urol 7(6):654–657CrossRefPubMed
18.
Zurück zum Zitat Chertin B, Arafeh WA, Zeldin A, Ostrovsky IA, Kocherov S (2013) Endoscopic correction of VUR using vantris as a new non-biodegradable tissue augmenting substance: three years of prospective follow-up. Urology 82(1):201–204CrossRefPubMed Chertin B, Arafeh WA, Zeldin A, Ostrovsky IA, Kocherov S (2013) Endoscopic correction of VUR using vantris as a new non-biodegradable tissue augmenting substance: three years of prospective follow-up. Urology 82(1):201–204CrossRefPubMed
20.
Zurück zum Zitat Kocherov S, Ulman I, Nikolaev S, Corbetta JP, Rudin Y, Slavkovic A, Dokumcu Z, Avanoglu A, Menovshchikova L, Kovarskiy S (2014) Multicenter survey of endoscopic treatment of vesicoureteral reflux using polyacrylate-polyalcohol bulking copolymer (vantris). Urology 84(3):689–693CrossRefPubMed Kocherov S, Ulman I, Nikolaev S, Corbetta JP, Rudin Y, Slavkovic A, Dokumcu Z, Avanoglu A, Menovshchikova L, Kovarskiy S (2014) Multicenter survey of endoscopic treatment of vesicoureteral reflux using polyacrylate-polyalcohol bulking copolymer (vantris). Urology 84(3):689–693CrossRefPubMed
22.
Zurück zum Zitat Alizadeh F, Mazdak H, Khorrami MH, Khalighinejad P, Shoureshi P (2013) Postoperative ureteral obstruction after endoscopic treatment of vesicoureteral reflux with polyacrylate polyalcohol copolymer (Vantris®). J Pediatr Urol 9(4):488–492CrossRefPubMed Alizadeh F, Mazdak H, Khorrami MH, Khalighinejad P, Shoureshi P (2013) Postoperative ureteral obstruction after endoscopic treatment of vesicoureteral reflux with polyacrylate polyalcohol copolymer (Vantris®). J Pediatr Urol 9(4):488–492CrossRefPubMed
Metadaten
Titel
Comparison of histopathological characteristics of polyacrylate polyalcohol copolymer with dextranomer/hyaluronic acid after injection beneath the bladder mucosa layer: a rabbit model
verfasst von
Abdol-Mohammad Kajbafzadeh
Shabnam Sabetkish
Reza Khorramirouz
Nastaran Sabetkish
Publikationsdatum
16.02.2017
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 5/2017
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-017-1540-z

Weitere Artikel der Ausgabe 5/2017

International Urology and Nephrology 5/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.